ENROLLING NOW - 2
2. An Open Label-Extension trial to assess the long-term safety of ZX008 (Fenfluramine Hydrochloride) oral solution as an Adjunctive Therapy in children and young adults with Dravet Syndrome.
PI: Juliann Paolicchi, MD
Sponsor: Zogenix Pharmaceutical
Key Inclusion Criteria:
* Subject has satisfactorily completed the core study in the opinion of the Investigator and the Sponsor.
* Subject's parent/ caregiver has been compliant with diary completion during the core study in the opinion of the investigator (eg, at least 90% compliant).
* Age 2 to 18
* Known Hypersensitivity to fenfluramine
* Hx of pulmonary Hypertension
* Current or past hx of heart disease or cerebrovascular disease.